Cooley advised NeuExcell Therapeutics on the deal. NeuExcell Therapeutics, a neurodegenerative disease gene therapy company, announced its $15 million+ Series Pre-A+ financing round. Investors in the round...
NeuExcell Therapeutics’ $15 Million Series Pre-A+ Financing Round
Structure Therapeutics’ $185.3 Million IPO
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...